Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin
Journal Article
Overview
publication date
- December 1, 2004
has subject area
- Aminoglycosides - Doxorubicin
- Biological Science Disciplines - Drug Design
- Blood Proteins - Vitronectin
- Breast Diseases - Breast Neoplasms
- Cell Adhesion
- Cell Membrane
- Cell Physiological Phenomena - Cell Proliferation
- Chemistry - Drug Design
- Drug Therapy - Antineoplastic Combined Chemotherapy Protocols
- Drug Therapy, Combination - Antineoplastic Combined Chemotherapy Protocols
- Extracellular Matrix Proteins - Vitronectin
- Female
- Formaldehyde
- Growth - Cell Proliferation
- Humans
- Hydrocarbons, Aromatic - Doxorubicin
- Investigative Techniques - Drug Design
- Membrane Proteins - Integrin alphaVbeta3
- Neoplasms by Site - Breast Neoplasms
- Peptide Fragments
- Polycyclic Compounds - Doxorubicin
- Prodrugs
- Proteins - Integrin alphaVbeta3
- Proteins - Vitronectin
- Receptors, Immunologic - Integrin alphaVbeta3
- Receptors, Vitronectin
- Receptors, Vitronectin - Integrin alphaVbeta3
- Therapeutics - Antineoplastic Combined Chemotherapy Protocols
- Toxicity Tests - Inhibitory Concentration 50
- Toxicological Phenomena - Inhibitory Concentration 50
- Tumor Cells, Cultured
Date in CU Experts
- September 9, 2013 9:18 AM
Full Author List
- Burkhart DJ; Kalet BT; Coleman MP; Post GC; Koch TH
author count
- 5
citation count
- 69
published in
- Molecular Cancer Therapeutics Journal
Other Profiles
International Standard Serial Number (ISSN)
- 1535-7163
Electronic International Standard Serial Number (EISSN)
- 1538-8514
Additional Document Info
start page
- 1593
end page
- 1604
volume
- 3
issue
- 12